arrow
E

Elisabetta Metafuni

Department of Laboratory and Hematological Sciences
H指数:20
被引数:1,201
浏览量:0

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Early deterioration and subsequent recovery of nursing complexity after CAR-T therapy: a prospective score-based analysis

CAR-T治疗后护理复杂性的早期恶化和后续恢复:一项基于评分的前瞻性分析

2026-09-050
PRE
TP53 Mutations Unfavorably Impact the Outcomes of Myelofibrosis Patients with or Without Hematopoietic Stem Cell Transplantation: A Single-Center Study and Meta-Analysis

TP53突变对接受或不接受造血干细胞移植的骨髓纤维化患者结局的不利影响: 一项单中心研究和荟萃分析

2026-05-250
OAAI
Pegcetacoplan Delivers Real-World Therapeutic Benefits and Reduces Disease Burden for Patients With Paroxysmal Nocturnal Haemoglobinuria: A Systematic Literature Review of Pegcetacoplan Real-World Clinical and Patient-Reported Outcomes

pegcetacoplan为阵发性睡眠性血红蛋白尿症患者带来真实世界治疗益处并减轻疾病负担:pegcetacoplan真实世界临床及患者报告结局的系统文献综述

2026-05-010
OA
Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT

异基因造血细胞移植后出血性膀胱炎的发病率和结局:EBMT传染病工作组的一项调查

2026-03-260
PRE
Unrelated donor transplantation for relapsed refractory aplastic anemia, with quadruple GvHD prophylaxis

无关供者移植治疗复发难治性再生障碍性贫血,联合四联GvHD预防

2025-12-020
PRE
Transplant conditioning intensity (TCI) score predicts allo-HCT outcomes in patients with myelofibrosis: a study of the Chronic Malignancies Working Party of EBMT

移植预处理强度(TCI)评分可预测骨髓纤维化患者的allo-HCT结局:EBMT慢性恶性疾病工作组的研究

2025-10-150
OA
Time to anti-cancer treatment resumption after SARS-CoV-2 infection in patients with active haematological diseases undergoing combined antiviral treatments

SARS-CoV-2感染后,活动性血液疾病患者在接受联合抗病毒治疗情况下重新开始抗癌治疗的时间

2025-10-010
OAAI
Characterization of Breakthrough Hemolysis in Patients With Paroxysmal Nocturnal Hemoglobinuria: An International Multicenter Experience

阵发性夜间血红蛋白尿症患者突破性溶血的特征:一项国际多中心经验

2025-08-110
OAAI
Improved outcome of COVID-19 over time in patients treated with CAR T-cell therapy: Update of the European COVID-19 multicenter study on behalf of the European Society for Blood and Marrow Transplantation (EBMT) Infectious Diseases Working Party (IDWP) and the European Hematology Association (EHA) Lymphoma Group
LEUKEMIA
IF13.4
2024-07-230
OAAI
Real World Use of Tixagevimab/Cilgavimab Pre-Exposure Prophylaxis of COVID-19 in Immunocompromised Individuals: Data from the OCTOPUS Study
2024-07-170
OAAI
Pure red cell aplasia among ABO mismatched hematopoietic stem cell transplant recipients: a 13-years retrospective study and literature review
2024-07-022
OAAI
Listeria monocytogenes Infections in Hematopoietic Cell Transplantation Recipients: Clinical Manifestations and Risk Factors. A Multinational Retrospective Case-Control Study from the Infectious Diseases Working Party of the European Society for Blood and Marrow Transplantation
2024-07-013
PRE
Endothelial Activation and Stress Index (EASIX) to predict mortality after allogeneic stem cell transplantation: a prospective study
2024-01-092
OAAI